WEKO3
アイテム
癌遺伝子治療に有用なアデノウイルスベクターの開発戦略
http://hdl.handle.net/10470/27020
http://hdl.handle.net/10470/27020864caaec-433d-465c-9acc-bde2af8aebcf
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
公開日 | 2010-08-10 | |||||||||
タイトル | ||||||||||
タイトル | 癌遺伝子治療に有用なアデノウイルスベクターの開発戦略 | |||||||||
言語 | ||||||||||
言語 | jpn | |||||||||
資源タイプ | ||||||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||
資源タイプ | journal article | |||||||||
別タイトル | ||||||||||
その他のタイトル | Effective Strategies for Cancer Gene Therapy using Adenovirus Vectors | |||||||||
著者名 |
関, 敏郎
× 関, 敏郎
× 高野, 加寿恵
|
|||||||||
著者別名 | ||||||||||
姓名 | SEKI, Toshiro | |||||||||
著者別名 | ||||||||||
姓名 | TAKANO, Kazue | |||||||||
出版者 | ||||||||||
出版者 | 東京女子医科大学学会 | |||||||||
受付日付 | ||||||||||
日付 | 2010-08-10 | |||||||||
日付タイプ | Created | |||||||||
ISSN | ||||||||||
収録物識別子タイプ | ISSN | |||||||||
収録物識別子 | 0040-9022 | |||||||||
NCID | ||||||||||
収録物識別子タイプ | NCID | |||||||||
収録物識別子 | AN00161368 | |||||||||
書誌情報 |
東京女子医科大学雑誌 巻 75, 号 12, p. 460-469, 発行日 2005-12 |
|||||||||
著者版フラグ | ||||||||||
出版タイプ | VoR | |||||||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||
抄録 | ||||||||||
内容記述タイプ | Abstract | |||||||||
内容記述 | Adenovirus vectors (Ads) have been employed for a wide variety of cancer gene therapy applications to date. This utility has derived principally from the unparalleled ability of these agents to accomplish efficient gene delivery to tumor targets. Unfortunately, translation of these advantages has been more difficult to accomplish in human clinical gene therapy trials for cancer. Critical problems to overcome are low efficiency and lack of selectivity of currently available gene transfer systems. In the first instance, it has been recognized that tumor cells manifest a relative deficiency of the primary adenovirus receptor, coxsackievirus and adenovirus receptor (CAR). This CAR deficiency renders tumor cells resistant to Ad thus limiting the therapeutic advantages of this vector. In addition, Ad localizing within the systemic circuit exhibits a marked hepatotropism. Adaptation of Ad for cancer gene therapy applications would thus ideally embody these two mandates-the ability to accomplish CAR-independent gene delivery as a means to improve vector efficiency for tumor targets and the ability to avoid liver sequestration as a means to limit potential vector related toxicity. Herein, we report novel strategies to achieve these goals and thereby improve the utility of Ad for cancer gene therapy applications. | |||||||||
著者所属 | ||||||||||
東京女子医科大学医学部第二内科学 | ||||||||||
著者所属 | ||||||||||
東京女子医科大学医学部第二内科学 | ||||||||||
著者キーワード | ||||||||||
主題Scheme | Other | |||||||||
主題 | gene therapy | |||||||||
著者キーワード | ||||||||||
主題Scheme | Other | |||||||||
主題 | cancer | |||||||||
著者キーワード | ||||||||||
主題Scheme | Other | |||||||||
主題 | adenovirus | |||||||||
著者キーワード | ||||||||||
主題Scheme | Other | |||||||||
主題 | CAR | |||||||||
著者キーワード | ||||||||||
主題Scheme | Other | |||||||||
主題 | targeting |